Royalty Report: Diagnostic, Medical, Assay – Collection: 329696

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 20

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 20

Primary Industries

  • Diagnostic
  • Medical
  • Assay
  • Cancer
  • Drugs
  • Test/Monitoring
  • Proteins
  • Immune
  • Device
  • Genome
  • Technical Know How
  • Antibody
  • Supply
  • Biotechnology
  • Environmental Control
  • Food
  • DNA
  • Bacterial Infection
  • Surgical
  • Molecular
  • HIV / AIDs
  • Therapeutic
  • nucleic acid

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 329696

License Grant
Licensor of the United Kingdom grants a world-wide, exclusive sublicense under the University Patent Rights and a world-wide, exclusive license under the Licensor Patent Rights and Licensor Confidential Information to develop, use, manufacture, have manufactured, market and sell Licensed Products, and to practice the processes and procedures of such Patent Rights and Confidential Information.  The amendment further defines the licensed product.

Licensor shall disclose to Licensee all existing Chemiluminescence Technology which is necessary or in any way useful to enable Licensee to develop, use, manufacture, have manufactured, market and sell Licensed Products.  The Parties shall continue to negotiate in good faith a Development Agreement whereby Licensor shall assist Licensee in the development of Licensed Products.

License Property
Licensor has acquired the exclusive right and license to develop, manufacture, market and sell, either by itself or with such other parties as University and Licensor shall determine, clinical diagnosis kits and/or components thereof, and/or other related products, incorporating the University Technology covered by the University Patent Rights, with the right to grant sublicenses.

The licensed University technology consists of certain compounds, materials, processes, and procedures relating to the use of stable derivatives of aryl acridinium esters as labeling agents in chemiluminescent assays such that assay reagents may be labeled with such derivatives to very high densities, and such labeled assay reagents, following the triggering of a light emitting reaction, may be quantified or detected with high sensitivity by measuring or sensing the emitted light through simple photon counters.

Chemiluminescence Technology shall mean that body of knowledge inclusive of the Licensor Confidential Information and any and all knowledge now or hereafter disclosed in the University Patent Rights or Licensor Patent Rights.

Licensed Products shall mean products for the diagnosis, detection, prognosis or monitoring of infectious disease agents and the diagnosis, detection, prognosis or monitoring of oncogenes or various forms of cancer, which incorporate Licensor Confidential Information and/or subject matter within the scope of any valid claims of any patent in the University Patent Rights or the Licensor Patent Rights and utilize nucleic acid hybridization technology in such diagnosis, detection, prognosis or monitoring.

The patents relate to Luminescent Protein Labelling, Homogeneous Assay, Acridinium Label, and, Mass Photon Immunoassay.

The May 1989 amendment updates the Licensed Products to mean products for the diagnosis, detection, prognosis or monitoring of infectious disease agents, for the diagnosis, detection, prognosis or monitoring of oncogenes or various forms of cancer and for the detection or monitoring of levels of all bacteria as a screen for corrosion-causing microorganisms, through the use of probes to conserved sequences, in oilfield produced water and other specimens associated with the petroleum industry and use of petroleum products and for the detection or monitoring of two types of corrosion-causing microorganisms which have been isolated by British Petroleum (one of which is believed to be a member of the genus Desulfovibrio and the other of which is believed to be a member of the genus Desulfotomaculum, which incorporate Bioanalysis Confidential Information and/or subject matter within the scope of any valid claims of any patent in the University Patents Rights or the Licensor Patent Rights and utilize nucleic acid hybridization technology in such diagnosis, detection, prognosis or monitoring.

Field of Use
The field of use is nucleic acid hybridization technology, initially in the fields of infectious disease and oncogenes/cancer.

IPSCIO Record ID: 329702

License Grant
This amendment between the Licensor of the United Kingdom and Licensee adds intellectual property description, patent information and royalty information.
License Property
The Agreement shall be amended to add the following terms
–  Prior AE Compounds shall mean those acridinium ester compounds disclosed and claimed in United States patent no. 4,946,958.
–  Additional AE Compounds shall mean all acridinium ester compounds other than those disclosed and claimed ; including, but not limited to, the acridinium ester compounds incorporated into Licensees, dual kinetic assay products as of the date of this Third Amendment, 2-Me-AE and o-F-AE.
Field of Use
The field of use is nucleic acid hybridization technology, initially in the fields of infectious disease and oncogenes/cancer.

IPSCIO Record ID: 237230

License Grant
The University of Wales grants to the Licensee registered in England
– an exclusive license to use the Technical Information and under the Licensors copyright to use the Process to manufacture Products; and
– an exclusive license to use sell or otherwise deal in Products manufactured under the license anywhere in the Territory.

The Licensor hereby agrees to grant to the Licensee
– an exclusive license under the Patent Rights to use the Process to manufacture Products; and
– an exclusive license to use sell or otherwise deal in Products manufactured under the license anywhere in the Territory.

License Property
The Licensor has developed and is the beneficial owner of a substantial body of valuable Technical Information relating to the measurement of analytes based upon the phenomenon of chemiluminescence which is applicable to immunoassay binding protein and other assay systems and is the beneficial owner of the Patent Rights.

Process is the chemiluminescence technology and defined in the Patent Rights.

Products are clinical diagnostic kits and/or components thereof and/or any other products incorporating the Process.

Field of Use
The Licensee wishes to use such information and to work under the said Patent Rights in order to manufacture, use, sell or otherwise deal in the said chemiluminescence technology save and except the excluded uses.

IPSCIO Record ID: 237229

License Grant
The University of Wales grants to the Licensee, also of Wales, an exclusive right and license to develop manufacture market and sell either by itself or with such other parties as Licensee and Licensor shall determine clinical diagnostic kits and/or components thereof and/or any other related products incorporating the Chemiluminescence Technology covered by the Patents.
License Property
University has developed techniques for the measurement of the presence of antibodies binding proteins and other analytes based upon the phenomenon of chemiluminescence which it believes may be applicable to immunoassay binding protein and other assay systems.

The patents relate to Luminescent Protein Labelling, and, Homogeneous Assay.

Field of Use
Licensee has assisted in the development of the techniques and has a number of commercial contacts who would be interested in manufacturing and marketing clinical diagnostic kits components for such kits and other related products on a commercial scale and is also interested in manufacturing and marketing such kits and other products itself.

IPSCIO Record ID: 286051

License Grant
The Licensor of England grants the exclusive rights to make have made use and sell Products and to practice the methods described in the said Patent Rights to conduct clinical assays.

Licensor shall promptly after the date hereof disclose to Licensee all Proprietary Information owned or controlled by Licensor which is reasonably necessary to enable Licensee to make have made use and sell Products and to apply Chemiluminescence Technology to clinical diagnostic assay products and procedures and Licensor grants to Licensee the right and license to use such Proprietary Information to make or have made Products in the Countries identified and to use and sell Products and to perform clinical assays throughout the world.

Licensor agrees to grant to Licensee an exclusive license under all patent rights inventions know-how and proprietary information that it may hereafter come to own or control or shall have the right to sublicense during the Term of this Agreement and which cover or relate to improvements to Licensors licensed Patent Rights Products or to the assays agreed by Licensor and Licensee to enable Licensee to use such Patent rights inventions know-how and Proprietary Information to improve such Products and assays.

If Licensor develops new diagnostic immunoassay and binding protein tests based upon the Chemiluminescence Technology during the Term other than the assays identified and which are not improvements to such assays Licensor shall promptly and exclusively advise Licensee in writing of the availability of such assays and shall make available to Licensee all information in the possession of Licensor regarding such assays and shall give Licensee 120 days to make a proposal to Licensor whereby Licensee shall obtain licenses to make have made use and sell such assays Licensor shall accept or reject Licensees proposal.

License Property
The Licensor property was granted to Licensor by a University, the rights to the techniques for the measurement of the presence of antibodies, binding proteins and other analytes based upon the phenomenon of chemiluminescence.  The University inventions are specifically pertaining to Chemiluminescence Technology.

The technology is a proprietary technique for measurements based upon the phenomenon of chemiluminescence for which the University has applied for patent protection.

The Chemiluminescence technology is the body of knowledge inclusive of the Universitys Patent Rights and Proprietary Information relating to the quantification of substances utilizing light energy emissions resulting from reactions involving such substances that is useful in immunoassay and binding protein assay systems.

The Products are Clinical diagnostic kits and components of diagnostic kits the manufacture sale or use of which would constitute an infringement of the Universitys Patent rights but for the licenses granted hereby or which incorporate to a substantial degree technical Proprietary Information.

Field of Use
The field of use is measurement technology to clinical diagnostic immunoassay and binding protein assay systems developed.

IPSCIO Record ID: 329692

License Grant
Prior to the Effective Date of this Agreement, the Parties have been involved in collaborative efforts to jointly develop assays for the ANAIS Instrumentation.

By this agreement, the Parties shall cooperate in the Development Transition and in the transfer of any information and Know-How necessary for Licensee to assume the development of the ANAIS Products.

Licensor grants a non-exclusive, non-transferable, worldwide license in the ANAIS Field to use the Licensor Technology to develop, make and have made, use, sell, offer for sale, have sold, and import the ANAIS Products, solely and exclusively for use on the ANAIS Instrumentation.

License Property
The ANAIS Instrument shall be an automated laboratory instrument for performing nucleic acid assays utilizing High Density DNA Probe Arrays.
Key BioChemistry Components include
– All enzymes used in transcription-based amplification for use in ANAIS Assays.
– All biochemical components used for amplification of amplicon of target with TMA, which is Licensors patents and technology relating to Nucleic Acid Sequence Amplification Methods.
– All probes, primers, and oligonucleotides used in ANAIS Assays.
– Nucleic acids used for ,positive and negative controls, standards, calibrators, and for quality control of ANAIS Assay components.

ANAIS products shall mean the following Probe Assays, in each case made, used, or sold under the license granted by Licensor and solely and exclusively for use on ANAIS Instrumentation
– Probe Assays for the detection, identification, quantification, and/or susceptibility testing for panels of microorganisms or agents (but specifically excluding single organisms) in specimens taken from humans, solely for the purpose of diagnosis and medical care of the persons from whom the tested samples were taken. A panel shall test for 10 or more distinct species of organisms or agents in the following groups of microorganisms
or agents  Bacteria; Viruses; Yeast/Fungi; or, Parasites.The panels shall be medically relevant.

– Probe Assays for the detection, identification, quantification, and/or susceptibility testing for an individual organism, drawn only from the groups or families listed below, in specimens taken from humans, solely for the purpose of diagnosis and medical care of the persons from whom the tested samples were taken Hepatitis virus; HIV virus; Herpes virus; Human papilloma virus; HTLV Virus; Yeast; Fungus; Parasite; and, Bacterium other than Neisseria gonorrhoeae or Chlamydia trachomatis.

– Probe Assays for testing of sequences encoding human leukocyte antigens in specimens taken from humans and/or

– Probe Assays to detect and /or precisely identify microorganisms or agents including bacteria, yeast, viruses and parasites for use in quality control processes of water, food products, and/or previously developed pharmaceutical or cosmetic products, and/or identify foods coming or derived from plants and/or/ animals for the purpose of confirming anticipated source(s) of the food.

Assay shall mean a diagnostic process or procedure applied to a sample, or a portion of a sample, whereby a particular chemical compound, or a collection of compounds, or a portion of a chemical compound, is detected and optionally quantified.

Field of Use
The ANAIS Field shall mean
– the detection, identification, quantification, and/or susceptibility testing of organisms or agents causing human clinical infectious diseases, as present in the human body, solely for the purpose of diagnosis and medical care of the persons from whom the tested samples were taken;
– testing for sequences encoding human leukocyte antigens;
– testing for microorganisms or agents, including bacteria, yeast, viruses and parasites in quality control processes of water, food products, and/or previously developed pharmaceutical or cosmetic products; and/or
– testing for the purposes of identifying genetically-modified foodstuffs or identifying animal species in foodstuffs.

The ANAIS Field specifically does not include testing for infectious agents in blood and blood products intended for transfusion, or the testing for infectious agents in blood in connection with organ transplants, or the testing of specimens from non-human animals or environmental sources except as specifically provided above, even if such testing is for the purpose of detecting or identifying organisms which are associated with infectious diseases in man.

IPSCIO Record ID: 329693

License Grant
Licensor grants a non-exclusive, non-transferable, worldwide license in the VIDAS Field to use the Licensor Technology solely to develop, make and have made, use, sell, offer for sale, have sold and import the VIDAS Products, solely and exclusively for use on the VIDAS Instrumentation.
License Property
Licensor possesses technology, knowledge, know-how and proprietary rights pertaining to nucleic acid hybridization and amplification technologies, detection and identification technologies, including specific probes targeting ribosomal RNA and specific target sequences and regions, microbiological culture collections, Probe Assay formats, specimen collection and processing, multiple analyte detection technologies and related intellectual property.

VIDAS Instrumentation shall mean, collectively, the Licensee instrument system currently known as the VIDAS system and the Licensee instrument system currently known as the mini-VIDAS system, as such systems existed on the date of the VIDAS Agreement and as hereafter modified or supplemented by additional instrumentation or devices as required to accommodate VIDAS Products, each of which modified and/or supplemented systems shall consist of instrumentation which is generally sold for processing and interpreting both Probe Assays and immunoassays, excluding, in any event, all VIDAS Products to be run on such instrumentation, provided, however, that such term may include a Probe Assay-only VIDAS system that Licensee may elect to develop at its expense, and provided, further, such modified and/or supplemented Probe Assay-only instrumentation system shall
–  be semi-automated, meaning it does not accept the sample container itself and performs all steps needed to produce the tests results.
–  use as its test format (i) a multi-well plastic cassette, currently referred to as a VIDAS strip which contains pre-dispensed reagents, tests for analytes and controls which is manually loaded into and resident in individual incubation and processing slots, and (ii) a pipette tip, currently referred to as an SPA, containing immobilized capture ligands; and
–   accommodate, on any single unit capable of stand-alone operation of such modified and/or supplemented instrument system, no more than thirty (30) test cassettes at one time.

VIDAS Products shall mean the following Probe Assays, in each case made, used, or sold under the license granted by Licensor in this Agreement and solely and exclusively for use on VIDAS Instrumentation
–   VIDAS Initial Products, which shall mean, collectively, Probe Assays for the detection of Chlamydia trachomatis (VIDAS Probe CT); Probe Assays for the detection of Neisseria gonorrhoeae (VIDAS Probe GC), Probe
Assays for the detection of Neisseria gonorrhoeae and/or Chlamydia trachomatis in combination VIDAS CT/GC Screen and Probe Assays for the detection of Mycobacterium tuberculosis (VIDAS Probe MTB)
–   VIDAS QHIV Product, means the Probe Assay for the quantitative detection of human immunodeficiency virus which has been the subject of joint Parties development efforts prior to the Effective Date. IF Licensee elects to develop an alternative QHIV probe assay for the VIDAS Instrumentation and a new regulatory submission is required for such assay, then (i) if Licensee ceases to market the original VIDAS QHIV Product and markets only the alternative QHIV probe assay, such alternative QHIV probe assay shall thereafter be prospectively considered to be the VIDAS QHIV Product for purposes of this Agreement, but (ii) if Licensee continues to market the original VIDAS QHIV Product and also markets the alternative QHIV probe assay, such alternative QHIV probe assay shall be considered to be a VIDAS Future Infectious Disease Product for purposes of this Agreement.
–  VIDAS HLA Product, which shall mean Probe Assays for the detection and quantification of sequences encoding·human leukocyte antigens;
–  VIDAS Food Testing Products, which shall mean Probe Assays for the detection of microorganisms in any and all materials associated with the production (including quality control) of foodstuffs or beverages, including water, intended for human or animal consumption.
–  VIDAS Future Infectious Disease Products, which shall mean Probe Assays, other than the VIDAS Initial Products and VIDAS QHIV Product, for detection, identification, quantification of, and/or susceptibility testing for agents causing human clinical infectious diseases, as present in the human body, solely for the purpose of diagnosis and medical care of the persons from whom the tested samples were taken.
–  VIDAS Other Future Products, which shall mean any Probe Assays which are directed at one or more Option Targets selected by Licensee.

Assay shall mean a diagnostic process or procedure applied to a sample, or a portion of a sample, whereby a particular chemical compound, or a collection of compounds, or a portion of a chemical compound, is detected and optionally quantified.

Probe Assay shall mean an Assay using a nucleic acid as a necessary and active reagent or which detects a set of nucleic acid sequences or a specific nucleic acid sequence, as a means of obtaining useful information relevant to the sample being assayed.

Key Biochemistry Components or KBCs shall mean (a) the lysing tubes, enzymes, nucleic acids and other biochemical compounds and reagents.  Key Biochemistry Components are
–  All enzymes used in transcription-based amplification, including TMA and variations and improvements to TMA, for use in VIDAS Assays.
–  All biochemical components used for amplification of amplicon of target with TMA.
–  All probes, primers, and oligonucleotides used in VIDAS Assays.
–  Nucleic acids used for positive and negative controls, standards, calibrators, and for quality control of VIDAS Assay components and VIDAS kits.

Field of Use
Technology covers semi-automated probe assays and advanced fully-automated, probe assays for the diagnosis of infectious diseases and detection of food pathogens.

Licensee and its Affiliates maintain and operate a worldwide network of semi-automated instruments known as VIDAS and mini-VIDAS for the diagnosis of infectious disease and other indications.

VIDAS Field shall mean
–  the detection, identification, quantification, and/or susceptibility testing of agents causing human clinical infectious diseases, as present in the human body, solely for the purpose of diagnosis and medical care of the persons from whom the tested samples were taken;
–  testing for sequences encoding human leukocyte antigen;
–  testing for microorganisms in any and all materials associated with the production, including quality control, of foodstuffs or beverages, including water, intended for human or animal consumption;
–  testing for any analyte listed and selected by Licensee, as present in a clinical sample from the human body, solely for the purpose of diagnosis and medical care of the person from whom the tested sample was taken.

The VIDAS Field specifically does not include testing for infectious agents in blood and blood products intended for transfusion, or the testing for infectious agents in blood in connection with organ transplants, or the testing of specimens from non-human animals or environmental sources except as specifically provided above, even if such testing is for the purpose of detecting or identifying organisms which are associated with infectious diseases in man.

The target markers are
–  Cancer Markers
1. Prostase,
2. Mammaglobin,
3. Kras,
4. p53,
5. Cancer related mutations of the mitoch9ndrial RNA in the D-Loop regulatory region, the NADH (nicotinamide adenine dinucleotide) region, and the dehydrogenase subunit 4.
–  Cardiac Markers
6. Factor II (Prothrombiri) mutation (20210)
7. Factor V Leiden mGtation
–  Alzheimer Markers
8. ApoE
9. presenilin,
–  Sepsis Markers
10. Sepsis specific cytokine.

IPSCIO Record ID: 286052

License Grant
Licensor grants to a worldwide, nonexclusive, nontransferable right and license, with no right to grant any sublicenses, to make, have made, use, and sell Licensed products. Accordingly, the license includes the right of Licensee and purchasers of its Licensed products to practice methods covered by the Licensed patents and Licensed patent applications only by using such licensed products.
License Property
Licensor owns all rights to United States Patent titled Heterogenous chemiluminescent specific binding assay, and, its corresponding foreign-filed counterparts covering certain chemiluminescent specific binding assay methods and reagent systems.

Licensed Product shall mean a product for performing a Chemilumniescent Immunoassay only, and no other product, which when made, used, or sold would infringe a claim of a Licensed patent.

Chemilumniescent Immunoassay shall mean a liquid-phase heterogeneous chemiluminescent assay employing a chemiluminescent reactant as label and wherein the substance or condition to be determined, i.e., analyte of interest, is determined by binding thereto of an antibody or other specific binding protein.

Field of Use
Licensee intends to develop and market instruments and reagent systems for performing chemiluminescent immunoassays.

IPSCIO Record ID: 249745

License Grant
Licensor grants a non-exclusive license under the Licensed Patents in the Field in the Territory during the License Term, to make, have made, use, offer to sell, sell and import Licensed Services.  Licensee shall have the right to sublicense.
License Property
The patents and technology relate to Colorectal Cancer Assay, meaning any colorectal cancer diagnostic or monitoring test including but not limited to screening, diagnosis, staging, monitoring and pharmacogenetic testing.
Field of Use
The field shall mean colorectal cancer assays used for specialty testing.

IPSCIO Record ID: 383575

License Grant
Licensor of Switzerland grants a non-exclusive and non-transferable license, without the right to sublicense, under the Licensed Patents in the Territory with the rights to
—  incorporate Licensed Products into Licensee’s Complete Diagnostic Kits,
—  make, offer to sell and sell such Complete Diagnostic Kits in the Licensed Field, and
—  convey with the sale of such Complete Diagnostic Kits the right to use the Complete Diagnostic Kits under the Licensed Patents in the Licensed Field. Licensee’s right to use Complete Diagnostic Kits includes the right to perform evaluations and validations of Complete Diagnostic Kits, but specifically does not include the right to use Complete Diagnostic Kits for the performance of diagnostic services or testing, except that Licensee may use Complete Diagnostic Kits as End Users.
License Property
Licensor owns or controls certain Licensed Patents relating to chemically modified thermostable DNA polymerases, also known as Hot Start Enzymes, for use in polymerase chain reaction, or PCR, technology.

Licensed Product means a chemically modified thermostable DNA polymerase, the manufacture, use or sale of which is covered by one or more Valid Claims of the Licensed Patents, sold by Licensor, directly or through its distributor, or made and sold by a supplier licensed to make and sell the same.

Complete Diagnostic Kit means a Licensee manufactured and trademarked kit covered by one or more Valid Claims of the Licensed Patents, not covered by any Licensor patents other than the Licensed Patents and dedicated for use for PCR in the Licensed Field, and which Licensee manufactured and trademarked kit is comprised of, at a minimum, the essential active reagents used in the practice of PCR for nucleic acid testing in the Licensed Field. For the avoidance of doubt and for the sake of clarification, ASRs, Analyte Specific Reagents, are not Complete Diagnostic Kits.

U.S. Patent No. 5,677,152 — Issued October 14, 1997 (process and kit claims only) Nucleic Acid Amplification Using a Reversibly Inactivated Thermostable Enzyme

U.S. Patent No. 5,773,258 — Issued June 30, 1998 (process and kit claims only) Nucleic Acid Amplification Using a Reversibly Inactivated Thermostable Enzyme

U.S. Patent No. 6,127,155—Issued October 3, 2000 (reaction mixture claims only) Stabilized Thermostable Nucleic Acid Polymerase Compositions Containing Non-Ionic Polymeric Detergents

Field of Use
The Licensed Field means the field of use consisting of products or processes for the measurement, observation or determination of a disease, disease state or genetic predisposition to a disease, by detecting, quantitating, distinguishing and/or monitoring nucleic acids in samples of material originating from a human being for the medical management for that human being, but excluding
—  human identity testing, and
—  the following human disease targets Hepatitis A Virus, Hepatitis B Virus, Hepatitis C Virus, Human Immunodeficiency Virus, Human Papilloma Virus and Parvovirus B19; provided, however, that the said exclusions for the Human Papilloma Virus and Parvovirus B19 disease targets shall be limited to 3 years from the Effective Date after which time the Human Papilloma Virus and Parvovirus B19 disease targets shall be included within the Licensed Field subject to the royalty and other terms and conditions of this Agreement.

IPSCIO Record ID: 27510

License Grant
The Licensor gave an exclusively license to the Company of patent titled One-Step In Situ Hybridization Assay.
License Property
The patent applications owned or co-owned by the Company either seek to cover improvements in reagents and methods of performing an in situ hybridization process or seek to cover methods of identifying and isolating fetal cells for prenatal diagnosis by in situ hybridization.

Among its claims is one that recites a method for assaying nucleic acids in a sample of cells having substantially intact membranes. The claimed method consists essentially of the steps of contacting the sample with a medium comprising a fixative agent, a denaturing agent, a hybrid stabilizing agent, a buffering agent, a membrane pore-forming agent and at least one nucleic acid probe. The contacting is under hybridizing conditions. The sample is incubated with the medium in the presence of at least one detectable label, and duplex formation is detected by means of the label, wherein the method is capable of detecting as few as one to five copies of a target nucleic acid per cell. Another claim applies to the foregoing process, in which the detection is carried out by flow cytometry. The patent also contains claims for kits.

IPSCIO Record ID: 237261

License Grant
With this amended and restated agreement, Licensee desires a non-exclusive license under the patent applications, and patents that may issue therefrom, to develop and perform Assays and market Kits in one or more fields.

Licensor grants a non-exclusive immunity from suit in the Territory under Licensor Patent Rights
– to itself perform Licensed Assays;
– to make, have made, use, sell and promote Licensed Kits, and to pass on to end-user purchasers the right to use those Licensed Kits in the Licensed Fields under PHRI Patent Rights; and,
– to develop Licensed Assays and Licensed Kits, and to test Licensed Kits for quality control.

License Property
The licensed property is improvements in fluorescently labeled nucleic acid detection probes, and kits and assays employing such probes.  The patents include but are not limited to Hybridization Probes for Nucleic Acid Detection, Universal Stems, Methods and Kits, and, Detectably Labeled Dual Conformation Oligonucleotide Probes, Assays and Kits, and, Nucleic Acid Detection Probes Having Non-FRET Fluorescence Quenching and Kits and Assays Including Such Probes, and, Non-competitive Co-Amplification Methods, and, Wavelength-Shifting Probes and Primers and Their Use In Assays and Kits, and, Assays for short sequence Variants.
Field of Use
Licensed Fields shall mean the fields of Human In Vitro Diagnostics, Food Testing, and Environmental Testing.

Human In Vitro Diagnostics ( HIVD) shall mean the field of use comprising the in vitro measurement, observation or determination of one or more protein or nucleic acid targets in a sample obtained from a human being for medical management of that human being or for blood banking, bone marrow banking or similar banking of human tissues for human medical management, and pre-clinical uses and clinical trials for the foregoing uses, even if kits for such purposes are labeled Research Use Only or Investigational Use Only.

Food Testing shall mean the field of use comprising the in vitro measurement, observation, or determination of one or more protein or nucleic acid targets of an organism in a sample obtained from food and/or sources of food intended for human consumption in order to determine whether or not that food is fit for consumption.

Environmental Testing shall mean the field of use comprising the in vitro measurement, observation or determination of one or more protein or nucleic acid targets of microorganisms (including bacteria, yeast, viruses and parasites) for the purpose of detecting and/or monitoring environmental contamination in (a) materials associated with a manufacturing process, excluding samples of food intended for consumption, or (b) samples collected from air, soil, water or other liquids, particles or surfaces. Environmental Testing includes testing for the presence of microbiological agents used for bioterrorism and biowarfare.

IPSCIO Record ID: 383582

License Grant
In the original agreement, Licensor granted
— For the Layton and Stanford Patent Rights a nonexclusive, non-transferrable, limited sub-licensable, world-wide license under the Layton Patent Rights and the Stanford Patent Rights to practice and use the subject matter within the Layton Patent Rights and the Stanford Patent Rights in the Licensee Database Field of Use, Diagnostic Field of Use, the Homebrew Field of Use and the Personalized Research Field of Use.
— For the Montefiore Patent Rights, a non-transferrable, limited sub-licensable, world-wide license under the Montefiore Patent Rights to practice and use the subject matter within the Montefiore Patent Rights in the Licensee Database Field of Use, the Diagnostic Field of Use, the Homebrew Field of Use and the Personalized Research Field of Use.
— For the Cancer Marker Patent Rights, Licensor grants a non-transferrable, limited sub-licensable, world-wide license under the Cancer Marker Patent Rights to practice and use the subject matter within the Cancer Marker Patent Rights in the Licensee Database Field of Use, the Diagnostic Field of Use, the Homebrew Field of Use and the Personalized Research Field of Use, only with respect to cancer.
— For the Database Patent Rights and Seilhamer/Scott Patent Rights, Licensor grants a nonexclusive, non-transferable, non-sublicensable , world-wide license under the Database Patent Rights and Seilhamer/Scott Patent Rights to practice and use the subject matter within the Database Patent Rights and the Seilhamer/Scott Patent Rights in the Licensee Database Field of Use, the Diagnostic Field of Use, the Homebrew Field of Use, and the Personalized Research Field of Use.
— For the Sublicenses, Licensee shall have the right to grant sublicenses to third parties under such Patent Rights on a Product-by-Product basis to make, use, import, sell, and offer for sale Products developed by Licensee or its Affiliates.
— For the Co-Exclusive Licenses in the Homebrew and Diagnostic Fields of Use, Co-Exclusive shall mean that each Party has the right to exercise all of the rights under the Patent Rights in question in the field of use for which the parties have co-exclusive rights, without obligation to the other except to the extent provided in this Agreement, and neither Party alone has the right to grant sublicenses to third parties under such Patent Rights without express written consent of the other Party.
License Property
Cancer Marker Patent Rights shall mean all Valid Claims listed in any of the following patents and patent applications, to the extent that they are owned by Licensor with the right to license under this Agreement, and to the extent that they claim the composition of matter or use of any nucleic acids or proteins as markers or diagnostics for cancer.

The patents include
— Processes for Genetic Manipulations Using Promoters;
— Method for Detecting Pathological Conditions;
— Comparative Gene Transcript Analysis; and,
— Methods for Fabricating Micro Arrays of Biological Samples.

Field of Use
Licensee licenses various classes of patents from Licensor pertaining to the manipulation of genes, the detection of pathological conditions, comparative gene analysis, methods for fabricating tests of biological samples and the use of proteins as markers for cancers.

IPSCIO Record ID: 263967

License Grant
This license agreement is Included with an asset purchase agreement between this Licensee/Seller and a Third Party Buyer.

University hereby grants to Licensee a right and license to make, have made, use, lease, offer to sell, sell, otherwise commercially dispose of, export and import Licensed Products,  to practice Licensed Processes, in each case directly or by sublicense and only for commercial purposes, including providing services to third parties and for Licensees research and/or development in the Field of Use within the Territory during the Term.  

For the Option,  University hereby grants Licensee an option to acquire a non-exclusive, worldwide, royalty-bearing license within the Field of Use under the Optioned Patent Rights to make, have made. use, sell and offer for sale products, processes and services within the Field of Use.

License Property
The intellectual property relates to Sequencing of Biopolymers by Mass Spectrometry.

The Products associated with the Claimed Technologies are specifically SpectroCHlPs; QGE Software;  and,  QGE assays sold through Assays by Licensee. The Products may be amended from time to time.

Field of Use
The field of use is all uses.

IPSCIO Record ID: 223141

License Grant
The German Licensor hereby grants to Licensee an exclusive license (including the right to grant sublicenses) under the Licensed Patent Rights to conduct research and to develop, make, use, offer for sale, sell and import Licensed Products and to provide Services in the Territory.
License Property
Licensed Patent Rights shall mean (a) those certain patent applications and patents listed hereto; (b) all patents that have issued or in the future issue from such foregoing patent applications, including utility, model and design patents and certificates of invention; (c) all patents that have issued or in the future issue from any patent application that claims priority from, or common priority with, any of the foregoing patent applications, including utility, model and design patents and certificates of invention; and (d) all divisionals, continuations, continuations-in-part, reissues, renewals, extensions or additions to any such foregoing patent
applications and patents.

W003023057 (PCT /EP02/05489) – Method and Diagnosis Kit for Selection and/or for Qualitative and/or Quantitative Detection of Cells

Licensed Products shall mean in-vitro diagnostic assays to isolate, detect, identify, quantify, or test for drug susceptibility of, one or more proteins or nucleic acid sequences as diagnostic indicators for the presence of prostate cancer and/or bladder cancer, for the purpose of research, diagnosis or medical care, the  manufacture, use, sale offer for sale or importation of which would, but for the license herein granted by AdnaGen to Gen-Probe, infringe one or more Valid Claims of the AdnaGen Patent Rights.

Field of Use
This agreement pertains to the medical industry relating to certain technology concerning the qualitative and quantitative detection of cells which may be useful in connection with nucleic acid diagnostic assays. The diagnostic indicators are used for the presence of prostate cancer and/or bladder cancer, for the purpose of research, diagnosis or medical care.

'Group 1 Additional Products' shall mean in-vitro diagnostic assays to isolate, detect, identify or quantify, or test for drug susceptibility of, one or more proteins or nucleic acid sequences as diagnostic indicators for the presence of kidney cancer, cervical cancer, and/or ovarian cancer, for the purpose of research, diagnosis or medical care, the manufacture, use, sale offer for sale or importation of which would, but for the license herein granted by AdnaGen to Gen-Probe, infringe one or more Valid Claims of the Licensed Patent Rights.

'Group 2 Additional Products' shall mean in-vitro diagnostic assays to isolate, detect, identify or quantify, or test for drug susceptibility of, one or more proteins or nucleic acid sequences as diagnostic indicators for the presence of lung cancer, colon cancer, and/or breast cancer, for the purpose of research, diagnosis or medical care, the manufacture, use, sale offer for sale or importation of which would, but for the license herein granted by AdnaGen to Gen-Probe, infringe one or more Valid Claims of the Licensed Patent Rights.

IPSCIO Record ID: 286050

License Grant
The Licensor of England grants a non-exclusive license, without sublicensing rights, under Licensed Patents to make, have made, use, and sell or otherwise dispose of Licensed Products bearing the name and trademark of Licensee prominently displayed thereon to End-Users, Authorized Distributors and Royalty-Bearing Distributors.
License Property
Licensor has the rights for the US patent titled Method of performing assay for analyte in liquid medium, as well as corresponding patents and patent applications applied for in the European Patent Office and in the United Kingdom, France, Germany, and Japan.

Class A Licensed Products shall mean any human, in vitro diagnostic immunoassay products, including but not limited to instruments, instrument kits, systems, assays or chemical products, but excluding assay products using genetic probe reagents or a combination of immunoassay reagents and genetic probe reagents, employing a labelled reagent to form a chemiluminescent label and another reagent which is bound to magnetically attractable particles, the manufacture, use or sale of which would, but for the license granted in Article II hereof, infringe one or more of the License Patents.

Class B Licensed Products shall mean any human, in vitro diagnostic genetic probe products, including but not limited to instruments, instrument kits, systems, assays, or chemical products,  including assay products using a combination of genetic probe reagents and immunoassay reagents, employing a labelled reagent to form a chemiluminescent label and another reagents which is bound to magnetically attractable particles, the manufacture, use or sale of which would, but for the license granted in Article II hereof, infringe one or more of the Licensed Patents.

Licensed Products shall mean Class A Licensed Products and Class B Licensed Products.

Field of Use
The field of use is for the conduct of human, in vitro diagnostic immunoassays and genetic probe assays for detection of an analyte in a human sample contained in a liquid medium characterized by the use of a labelled reagent which forms a chemiluminescent label system and another reagent bound to magnetically attractable particles.

IPSCIO Record ID: 286033

License Grant
Licensor grants the following licenses for the Licensed Field only, which shall be exclusive, for the Bacteriology Field and non-exclusive for the balance of the Licensed Field
—  A worldwide license under the Patent Rights, Know-How and Copyrights included in Licensor Licensed Core Technology and Licensor Collaboration Technology to import, use, distribute and sell Licensed DNA Probe Arrays, and to incorporate or cause the incorporation of such Licensed DNA Probe Arrays, through processes of manufacture, into Licensed Diagnostic Assays, and to manufacture and have manufactured Licensed Diagnostic Assays, and to use, import, distribute and sell Licensed Diagnostic Assays.

With respect to Other Licensed Diagnostic Products that are to be used solely with a DNA Probe Array that has 10 or fewer Probes/cm(2) and is not included as a High Density Probe Array (Low Density  Probe Array), Licensor agrees to grant a nonexclusive, worldwide license in the Licensed Field under the Patent Rights included in the Licensor Licensed  Core Technology and the Licensor Collaboration Technology to make, have made,  use, import, distribute and sell and  under the Know-how and Copyrights included in the Licensor Licensed Core Technology and the Licensor Collaboration Technology to make, have made, copy, display, distribute, use, import and sell, all such Other Licensed Diagnostic Products for use with such Low Density Probe Arrays solely for use in the Licensed Field.

In addition to the foregoing license, Licensor grants with respect to Licensor Collaboration Technology, a nonexclusive, worldwide, research-use only license to use the Licensor Collaboration Technology outside of the Licensed Field for Licensees own research purposes pertaining to Clinical Diagnostics, and for the Licensed Field for Licensees purposes pertaining to this Collaboration and research and development in furtherance thereof.

For the option for non-exclusive Licenses in the Virology and HLA Fields, subject to pre-existing agreements, Licensor grants non-exclusive options to enter into non-exclusive licenses under Licensor Licensed Core Technology to expand Licensees products that would use Licensed DNA Probe Arrays to include categories of products for viral agents and products for the testing of human leukocyte antigens (HLA Class I and Class II allelic polymorphis) any condition, except for the diagnosis of cardiopulmonary disease to the extent that such rights have been previously granted on an exclusive basis to a third party (HLA option).

License Property
Licensed Diagnostic Product means a Licensed Diagnostic Assay or any Other Licensed Diagnostic Product.

Licensed Diagnostic Assay means a disposable diagnostic assay or reagent kit for use in Clinical Diagnosis,  which assay or kit incorporates a Licensed DNA Probe Array supplied by Licensor to Licensee pursuant to the Manufacturing Agreement or permissibly manufactured by Licensee in accordance with the Manufacturing Agreement.
    
Licensed DNA Probe Array means any High Density DNA Probe Array developed in the Collaboration, or based on specifications derived from prototypes so developed.

The Viral Agent Candidates include Adenovirus, Rotavirus, Herpes Simplex Virus Type II (when done in an STD panel), Enterovirus, Viral Influenza, Respiratory Syncytial Virus (as part of a respiratory panel), Viral encephalitis and Viral meningitis.

GeneChip system is the platform of choice for acquiring, analyzing and managing complex genetic information in order to improve the diagnosis, monitoring and treatment of disease.

GeneChip system consists of four integrated parts disposable DNA probe arrays containing genetic information on a chip housed in a cartridge, a fluidics station for introducing the test sample to the probe arrays, a scanner to read the data from the probe arrays, and software to control the instruments and to analyze and manage the genetic information. The GeneChip system is designed for use by pharmaceutical and biotechnology companies, academic research centers and reference laboratories.

Field of Use
The collaboration agreement is to develop GeneChip probe arrays for clinical diagnostic kits for bacterial identification and antibiotic resistance analysis.

The Licensed Field means the field which encompasses only the Bacteriology Field and the field of detection, identification and/or determination of resistance to treatment of four viral agents commonly included in bacteriology testing, to be elected by Licensee for use only in Clinical Diagnosis.

Bacteriology Field means the field of only detection and/or identification of bacterial and fungal microorganisms, and the determination of antibiotic resistance of such bacterial and fungal microorganisms, both for use in the Clinical Diagnosis of human disease.

IPSCIO Record ID: 289170

License Grant
Licensor grants to the Swiss Licensee a worldwide, semi-exclusive license, without the right to sublicense, under the Licensor Licensed Patents to research, develop, make, have made, import, use, offer for sale and sell Licensor Licensed Products for use in the Field.

For the Licensor Transplantation Field License, Licensor grants a worldwide, non-exclusive license, without the right to sublicense, under  Licensoe Licensed Patents to research, develop, make, have made, import, use, offer for sale and sell Licensor Licensed Products for use in the Transplantation Field.

License Property
The patent rights relate to the human immunodeficiency virus (HIV).

Products means reagents, compositions or kits suitable for use in the Field or the Transplantation Field.

Field of Use
The Licensee intended application is for use in assays for the detection of nucleic acid sequences for use in in vitro diagnostics (excusing use in Blood Screening, but without limiting the effect of the Blood Screening Agreement.

Field means the commercial use of human in vitro diagnostic products that detect nucleic acid sequences of HIV. Expressly excluded from the Field are products in Blood Screening; and products specifically labeled or promoted for use in the Transplantation Field.

Transplantation Field means the commercial use of products that detect nucleic acid sequences for the screening of any biological materials intended for transfusion or transplantation, in each case from any donor, including autologous donors, other than the transfusion or transplantation of blood or its derivatives, components or replacements.

IPSCIO Record ID: 146089

License Grant
Licensor grants a nonexclusive immunity from suit under PCR Technology solely to perform Licensed Services.

Licensor grants to Licensee the right to credit the Licensor as the source of PCR Technology in Licensees promotional materials and any other materials intended for distribution.

License Property
PCR or polymerise chain reaction is a nucleic acid amplification process.

Licensed Services means the performance of an IN VITRO diagnostic procedure utilizing PCR Technology to detect the presence, absence or quantity of a nucleic acid sequence associated with a human disease or condition within the Licensed field.

The Diagnostic product shall mean an assemblage of reagents, including but not limited to reagents packaged in the form of a kit, useful in performing a Licensed Service.

The licensed credit is 'This test is performed pursuant to a license agreement with Licensor.'

Field of Use
Licensor has expertise in validating, documenting and performing sophisticated diagnostic procedures.  The field is that of human IN VITRO diagnostics solely for the detection of genetic diseases, genetic predisposition to disease, agents associated with infectious diseases, cancer; and for tissue transplant typing, including testing performed on animal tissue intended for use in xenotransplantation; Parentage determination; disease management; and clinical trials.

IPSCIO Record ID: 291130

License Grant
Licensor hereby grants to Licensee, and Licensee hereby accepts from Licensor, a royalty-bearing, non exclusive, personal, non-transferable license under the Licensed Technology solely to perform Licensed Services within the Territory.

Licensor hereby grants to Licensee the right and Licensee accepts and agrees to credit Licensor as the source of its Licensed Technology rights in Licensees promotional materials and any other materials intended for distribution to Third Parties as follows

License Property
Licensor owns and has the right to grant licenses to practice under certain United States Patents describing and claiming, inter alia, nucleic acid amplification processes known as polymerase chain reaction ('PCR'), homogeneous PCR, and RT-PCR ('reverse transcription PCR').

Licensed Technology shall mean, subject to the following limitations, the Valid Claims of the United States patents listed in Agreement and any reissue or reexamination patents thereof. No rights under any kit claims of such patents are included in this definition or licensed under this Agreement. With the exception of the reaction mixture claims of United States Patents Nos. 5,804,375, 5,693,517, 5,476,774 and 6,127,155, the plasmid claims of the 5,476,774 patent, the primer claims of United States Patent No. 5,573,906, and the probe claims of United States Patent No. 5,110,920, no rights under any apparatus, device, composition of matter, reagent or substance claims of such patents are included in this definition or licensed under this Agreement.
4,683,195 – Process for amplifying, detecting, and/or-cloning nucleic acid sequences
4,683,202 – Process for amplifying nucleic acid sequences
4,965,188 – Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme

Diagnostic Product shall mean an assemblage of reagents, including but not limited to reagents packaged in the form of a kit, useful in performing a Licensed Service.

Licensed Service(s) shall mean the performance by Licensee of an in vitro procedure within the Licensed Field which utilizes the Licensed Technology. Licensed Services include, but are not limited to, any combination of the steps of collecting a sample for analysis, isolating nucleic acid sequences from the sample, amplifying one or more desired sequences, analyzing the amplified material, including sequence analysis, and reporting the results.

Field of Use
Licensed technology includes specified nucleic acid amplification processes, to perform certain polymerase chain reaction-based human in vitro clinical laboratory services.

Licensed Field shall mean the field of clinical laboratory services that detect the presence, absence and/or quantity of a nucleic acid sequence for the detection, diagnosis, confirmation, prognosis, management and/or treatment of a human disease or condition, including, but not limited to, such services to identify predisposition to disease, disease susceptibility, confirm disease, predict therapeutic effectiveness or monitor disease progress; used in the course of human clinical trials; for Parentage Determination; and for tissue transplant typing, including testing performed on animal tissue intended for use in xenotransplantation. Licensed Field shall specifically exclude any services performed for the screening of blood and/or blood products.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.